Ms. Sana Alajmovic, Co-Founder, CEO. Board member
Sana Alajmovic is Co-Founder and Chief Executive Officer of Sigrid Therapeutics AB, with successful experience in commercializing research and discovery by establishing partnerships with global top tier biopharmaceutical actors.
Sana Alajmovic has diverse experience in business development and management within the life science industry. Her previous positions include Head of Business Development for Drug Delivery at Nanologica, Business Development Manager at venture capital firm Serendipity Innovations Group and Project Manager for the Swedish-American Life Science Summit.
Before joining the life science industry, Sana was Managing Director for the venture capital firm Curitas within the private equity group Procuritas, Operations Manager for the charity foundation Chelha and Assistant Events & Marketing Manager at the Swedish-American Chamber of Commerce in New York.
Sana Alajmovic was selected as Top 10 Under 40 of 2019 by Genetic Engineering News (GEN) as well as Biospace 10 Life Science Innovators Under 40 to Watch in 2019. She was named one of Sweden’s 101 Super Talents by the leading Swedish business magazine Veckans Affärer in 2012.
2014-CEO, Co-founder and Board Member, Sigrid Therapeutics, Sweden
2015-2017 Board Member Berzelii Center EXSELENT, Sweden
2012-2014 Head of Business Development Nanologica, Sweden
2012 Business Development Manager Serendipity Innovations, Sweden
2012 Project Manager, The Swedish-American Life Science Summit, Sweden
2009-2011 Managing Director Curitas AB, Stockholm, Sweden
2009-2011 Head of Operations Chelha Foundation, Sweden
B.Sc., Business and Economics, Stockholm School of Economics